Načítá se...
ACTR-41. INTERIM RESULTS OF FIRST-IN-HUMAN STUDY USING NATIVIS VOYAGER™ SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
BACKGROUND: The Nativis Voyager® ulRFE™ system, a non-invasive investigational device, was studied in a first-in-human feasibility study to assess safety and feasibility of the treatment for recurrent glioblastoma (GBM). The anti-mitotic therapy delivers ultra-low radio frequency energy (ulRFE) prod...
Uloženo v:
| Vydáno v: | Neuro Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5693000/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.032 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|